高级检索
中华实验眼科杂志
期刊首页
过刊列表
高级检索
稿件发表
• 标准与规范 •
ENGLISH ABSTRACT
玻璃体视网膜淋巴瘤诊断及推荐治疗中国专家共识(2024年版)
中国抗癌协会眼肿瘤专家委员会
中国医药教育学会眼科专家委员会
作者及单位信息
·
DOI： 10.3760/cma.j.cn115989-20231204-00195
Chinese expert consensus recommendations for the diagnosis and treatment of vitreoretinal lymphoma (2024)
Ocular Oncology Committee of China Anti-Cancer Association
Ophthalmological Society of China Medicine Education Association
Zhou Nan
Wei Wenbin
Authors Info & Affiliations
Ocular Oncology Committee of China Anti-Cancer Association
Ophthalmological Society of China Medicine Education Association
Zhou Nan
Wei Wenbin
Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China
·
DOI： 10.3760/cma.j.cn115989-20231204-00195
1682
547
0
0
26
3
PDF下载
APP内阅读
摘要

玻璃体视网膜淋巴瘤(VRL)是一类少见的、高级别(即侵袭性)的淋巴结外淋巴瘤，其临床表现缺乏特异性，诊断困难，治疗策略不一致，对患者视力和生存均不利，也进一步限制了该领域的发展。中国抗癌协会眼肿瘤专委会和中国医药教育学会眼科专委会专家针对国内VRL领域实际情况，参考国内外最新研究数据和建议，经反复讨论，制定《玻璃体视网膜淋巴瘤诊断及推荐治疗中国专家共识(2024年版)》。该共识围绕VRL的临床表现、辅助检查、诊断流程、鉴别诊断、治疗及随访策略等方面分别给出意见，为临床医生诊断和治疗VRL提供参考，以进一步提高我国VRL的诊疗水平。

玻璃体视网膜淋巴瘤;诊疗规范;共识
ABSTRACT

Vitreoretinal lymphoma (VRL) is a rare and highly aggressive extranodal lymphoma with non-specific clinical features, making it difficult to diagnose and treat consistently.This poses a significant risk to both the patient's vision and survival that hinders the development of this field.To address this issue, experts from the Ocular Oncology Committee of China Anti-Cancer Association and Ophthalmological Society of China Medicine Education Association have formulated the Chinese expert consensus recommendations for the diagnosis and treatment of vitreoretinal lymphoma ( 2024) based on the latest research data and consensus recommendations for the disease.The consensus provides opinions on the clinical manifestations, auxiliary examination, diagnosis, differential diagnosis, treatment, and follow-up strategies of VRL, which serve as references for clinicians to improve the diagnosis and treatment level of this disease in China.

Vitreoretinal lymphoma;Rules of diagnosis and treatment;Consensus
Zhou Nan, Email: mocdef.3ab61emit99ohce;
Wei Wenbin, Email: mocdef.3ab61rtnibnewiew Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China
Copyright by Chinese Medical Association
No content published by the journals of Chinese Medical Association may be reproduced or abridged without authorization. Please do not use or copy the layout and design of the journals without permission.
All articles published represent the opinions of the authors, and do not reflect the official policy of the Chinese Medical Association or the Editorial Board, unless this is clearly specified.
引用本文

中国抗癌协会眼肿瘤专家委员会,中国医药教育学会眼科专家委员会. 玻璃体视网膜淋巴瘤诊断及推荐治疗中国专家共识(2024年版)[J]. 中华实验眼科杂志,2024,42(03)：209-218.

DOI:10.3760/cma.j.cn115989-20231204-00195

PERMISSIONS

Request permissions for this article from CCC.

评价本文
*以上评分为匿名评价

版权归中华医学会所有。

未经授权，不得转载、摘编本刊文章，不得使用本刊的版式设计。

除非特别声明，本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。

1　《玻璃体视网膜淋巴瘤诊断及推荐治疗中国专家共识(2024年版)》制定背景
玻璃体视网膜淋巴瘤(vitreoretinal lymphoma，VRL)是一类罕见的淋巴结外淋巴瘤，95%以上病理类型为非霍奇金弥漫大B细胞淋巴瘤，56%～90%的VRL患者最终会发生中枢神经系统受累，恶性程度高，可致盲、致死亡 [ 1 , 2 , 3 ]。然而，临床实践中VRL误诊率高，延迟诊断常见，症状出现与诊断的平均间隔为数月至数年不等 [ 4 , 5 ]。尽管VRL的发病率尚未见统计，但随着中枢神经系统淋巴瘤发病率的增高、人口老龄化及诊断水平的提高，预计未来VRL的发病率亦将增加。眼科多模式影像技术、生物样本检测及诊断性玻璃体切除技术不断发展和推广应用，使得对VRL也有了更多维度的认识。VRL的治疗方案，国内外相关研究建议虽均有涉及，且不断更新，但尚未就其诊疗建立共识。有鉴于此，中国抗癌协会眼肿瘤专委会、中国医药教育学会眼科专委会专家基于现有国内外临床研究文献、结合当前国内在VRL领域的实际情况和多学科专家临床诊疗经验及国外最新建议，讨论并制定《玻璃体视网膜淋巴瘤诊断及推荐治疗中国专家共识(2024年版)》，旨在为VRL的临床诊疗提供参考，避免延迟诊断，规范治疗方案，改善患者预后，进一步提高我国VRL诊疗水平。
试读结束，您可以通过登录机构账户或个人账户后获取全文阅读权限。
参考文献
[1]
Chan CC , Rubenstein JL , Coupland SE ,et al. Primary vitreoretinal lymphoma：a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium[J]. Oncologist， 2011，16(11)∶1589-1599. DOI： 10.1634/theoncologist.2011-0210 .
返回引文位置Google Scholar
百度学术
万方数据
[2]
Sagoo MS , Mehta H , Swampillai AJ ,et al. Primary intraocular lymphoma[J]. Surv Ophthalmol， 2014，59(5)∶503-516. DOI： 10.1016/j.survophthal.2013.12.001 .
返回引文位置Google Scholar
百度学术
万方数据
[3]
Carbonell D , Mahajan S , Chee SP ,et al. Consensus recommendations for the diagnosis of vitreoretinal lymphoma[J]. Ocul Immunol Inflamm， 2021，29(3)∶507-520. DOI： 10.1080/09273948.2021.1878233 .
返回引文位置Google Scholar
百度学术
万方数据
[4]
Grimm SA , Pulido JS , Jahnke K ,et al. Primary intraocular lymphoma：an International Primary Central Nervous System Lymphoma Collaborative Group Report[J]. Ann Oncol， 2007，18(11)∶1851-1855. DOI： 10.1093/annonc/mdm340 .
返回引文位置Google Scholar
百度学术
万方数据
[5]
Zhao XY , Cheng TT , Meng LH ,et al. Clinical features，diagnosis，management and prognosis of primary intraocular lymphoma[J/OL]. Front Oncol， 2022，12∶808511[2023-10-02]. http://www.ncbi.nlm.nih.gov/pubmed/35186744. DOI： 10.3389/fonc.2022.808511 .
返回引文位置Google Scholar
百度学术
万方数据
[6]
Inney TD , Adams RD . Reticulum cell sarcoma of the brain[J]. Arch Neur Psych， 1943，50(5)∶552-564. DOI： 10.1001/archneurpsyc.1943.02290230064007 .
返回引文位置Google Scholar
百度学术
万方数据
[7]
Russell DS , Marshall AH , Smith FB . Microgliomatosis；a form of reticulosis affecting the brain[J]. Brain， 1948，71(1)∶1-15. DOI： 10.1093/brain/71.1.1 .
返回引文位置Google Scholar
百度学术
万方数据
[8]
Chan CC , Buggage RR , Nussenblatt RB . Intraocular lymphoma[J]. Curr Opin Ophthalmol， 2002，13(6)∶411-418. DOI： 10.1097/00055735-200212000-00012 .
返回引文位置Google Scholar
百度学术
万方数据
[9]
Takase H , Arai A , Iwasaki Y ,et al. Challenges in the diagnosis and management of vitreoretinal lymphoma - clinical and basic approaches[J/OL]. Prog Retin Eye Res， 2022，90∶101053[2023-10-04]. http://www.ncbi.nlm.nih.gov/pubmed/35210172. DOI： 10.1016/j.preteyeres.2022.101053 .
返回引文位置Google Scholar
百度学术
万方数据
[10]
Soussain C , Malaise D , Cassoux N ．Primary vitreoretinal lymphoma：a diagnostic and management challenge[J]. Blood， 2021，138(17)∶1519-1534. DOI： 10.1182/blood.2020008235 .
返回引文位置Google Scholar
百度学术
万方数据
[11]
Deák GG , Goldstein DA , Zhou M ,et al. Vertical hyperreflective lesions on optical coherence tomography in vitreoretinal lymphoma[J]. JAMA Ophthalmol， 2019，137(2)∶194-198. DOI： 10.1001/jamaophthalmol.2018.5835 .
返回引文位置Google Scholar
百度学术
万方数据
[12]
Marchese A , Miserocchi E , Giuffrè C ,et al. Aurora borealis and string of pearls in vitreoretinal lymphoma：patterns of vitreous haze[J]. Br J Ophthalmol， 2019，103(11)∶1656-1659. DOI： 10.1136/bjophthalmol-2018-313491 .
返回引文位置Google Scholar
百度学术
万方数据
[13]
Gass JD , Trattler HL . Retinal artery obstruction and atheromas associated with non-Hodgkin's large cell lymphoma (reticulum cell sarcoma)[J]. Arch Ophthalmol， 1991，109(8)∶1134-1139. DOI： 10.1001/archopht.1991.01080080094039 .
返回引文位置Google Scholar
百度学术
万方数据
[14]
Guan W , Xiao Y , Zhao H ,et al. Spectral-domain optical coherence tomography biomarkers in vitreoretinal lymphoma[J]. Clin Exp Ophthalmol， 2023，51(2)∶144-153. DOI： 10.1111/ceo.14197 .
返回引文位置Google Scholar
百度学术
万方数据
[15]
Chen W , Gu J , Liu S ,et al. Perivascular flower-bud-like lesions on en face optical coherence tomography angiography in patients with vitreoretinal lymphoma[J]. Retina， 2022，42(11)∶2169-2175. DOI： 10.1097/IAE.0000000000003579 .
返回引文位置Google Scholar
百度学术
万方数据
[16]
Chen T , Liu Y , Wang Y ,et al. Evidence-based expert consensus on the management of primary central nervous system lymphoma in China[J/OL]. J Hematol Oncol， 2022，15(1)∶136[2023-10-06]. http://www.ncbi.nlm.nih.gov/pubmed/36176002. DOI： 10.1186/s13045-022-01356-7 .
返回引文位置Google Scholar
百度学术
万方数据
[17]
中国抗癌协会眼肿瘤专业委员会，中国医药教育协会眼科专业委员会．中国诊断性玻璃体切除手术专家共识(2022年)[J]. 中华眼科杂志， 2022，58(12)∶1017-1023. DOI： 10.3760/cma.j.cn112142-20220906-00440 .
返回引文位置Google Scholar
百度学术
万方数据
Ocular Oncology Committee of China Anti-Cancer Association,Ophthalmological Society of China Medicine Education Association. Chinese expert consensus on diagnostic vitrectomy for biopsy (2022)[J]. Chin J Ophthalmol， 2022，58(12)∶1017-1023. DOI： 10.3760/cma.j.cn112142-20220906-00440 .
Goto CitationGoogle Scholar
Baidu Scholar
Wanfang Data
[18]
Bechrakis NE , Foerster MH , Bornfeld N ．Biopsy in indeterminate intraocular tumors[J]. Ophthalmology， 2002，109(2)∶235-242. DOI： 10.1016/s0161-6420(01)00931-9 .
返回引文位置Google Scholar
百度学术
万方数据
[19]
Grimm SA , McCannel CA , Omuro AM ,et al. Primary CNS lymphoma with intraocular involvement：International PCNSL Collaborative Group Report[J]. Neurology， 2008，71(17)∶1355-1360. DOI： 10.1212/01.wnl.0000327672.04729.8c .
返回引文位置Google Scholar
百度学术
万方数据
[20]
Farkas T , Harbour JW , Dávila RM . Cytologic diagnosis of intraocular lymphoma in vitreous aspirates[J]. Acta Cytol， 2004，48(4)∶487-491. DOI： 10.1159/000326409 .
返回引文位置Google Scholar
百度学术
万方数据
[21]
Zaldivar RA , Martin DF , Holden JT ,et al. Primary intraocular lymphoma：clinical，cytologic，and flow cytometric analysis[J]. Ophthalmology， 2004，111(9)∶1762-1767. DOI： 10.1016/j.ophtha.2004.03.021 .
返回引文位置Google Scholar
百度学术
万方数据
[22]
Tan WJ , Wang MM , Ricciardi-Castagnoli P ,et al. Cytologic and molecular diagnostics for vitreoretinal lymphoma：current approaches and emerging single-cell analyses[J/OL]. Front Mol Biosci， 2020，7∶611017[2023-10-06]. http://www.ncbi.nlm.nih.gov/pubmed/33505989. DOI： 10.3389/fmolb.2020.611017 .
返回引文位置Google Scholar
百度学术
万方数据
[23]
Akpek EK , Maca SM , Christen WG ,et al. Elevated vitreous interleukin-10 level is not diagnostic of intraocular-central nervous system lymphoma[J]. Ophthalmology， 1999，106(12)∶2291-2295. DOI： 10.1016/s0161-6420(99)90528-6 .
返回引文位置Google Scholar
百度学术
万方数据
[24]
Caraballo JN , Snyder MR , Johnston PB ,et al. Vitreoretinal lymphoma versus uveitis：cytokine profile and correlations[J]. Ocul Immunol Inflamm， 2014，22(1)∶34-41. DOI： 10.3109/09273948.2012.752507 .
返回引文位置Google Scholar
百度学术
万方数据
[25]
Kuo DE , Wei MM , Knickelbein JE ,et al. Logistic regression classification of primary vitreoretinal lymphoma versus Uveitis by Interleukin 6 and interleukin 10 levels[J]. Ophthalmology， 2020，127(7)∶956-962. DOI： 10.1016/j.ophtha.2020.01.042 .
返回引文位置Google Scholar
百度学术
万方数据
[26]
Bonzheim I , Giese S , Deuter C ,et al. High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma：a valuable tool to improve diagnostic yield of vitreous aspirates[J]. Blood， 2015，126(1)∶76-79. DOI： 10.1182/blood-2015-01-620518 .
返回引文位置Google Scholar
百度学术
万方数据
[27]
Hiemcke-Jiwa LS , Ten Dam-van Loon NH , Leguit RJ ,et al. Potential diagnosis of vitreoretinal lymphoma by detection of MYD88 mutation in aqueous humor with ultrasensitive droplet digital polymerase chain reaction[J]. JAMA Ophthalmol， 2018，136(10)∶1098-1104. DOI： 10.1001/jamaophthalmol.2018.2887 .
返回引文位置Google Scholar
百度学术
万方数据
[28]
Lee J , Kim B , Lee H ,et al. Whole exome sequencing identifies mutational signatures of vitreoretinal lymphoma[J/OL]. Haematologica， 2020，105(9)∶e458-e460[2023-10-08]. http://www.ncbi.nlm.nih.gov/pubmed/33054063. DOI： 10.3324/haematol.2019.233783 .
返回引文位置Google Scholar
百度学术
万方数据
[29]
Tan WJ , Wang MM , Castagnoli PR ,et al. Single B-cell genomic analyses differentiate vitreoretinal lymphoma from chronic inflammation[J]. Ophthalmology， 2021，128(7)∶1079-1090. DOI： 10.1016/j.ophtha.2020.11.018 .
返回引文位置Google Scholar
百度学术
万方数据
[30]
Gu J , Jiang T , Liu S ,et al. Cell-free DNA sequencing of intraocular fluid as liquid biopsy in the diagnosis of vitreoretinal lymphoma[J/OL]. Front Oncol， 2022，12∶932674[2023-10-10]. http://www.ncbi.nlm.nih.gov/pubmed/35928872. DOI： 10.3389/fonc.2022.932674 .
返回引文位置Google Scholar
百度学术
万方数据
[31]
Zhou N , Xu X , Liu Y ,et al. A proposed protocol of intravitreal injection of methotrexate for treatment of primary vitreoretinal lymphoma[J]. Eye (Lond)， 2022，36(7)∶1448-1455. DOI： 10.1038/s41433-021-01657-0 .
返回引文位置Google Scholar
百度学术
万方数据
[32]
Zhang X , Zhang Y , Guan W ,et al. Development of diagnostic recommendations for vitreoretinal lymphoma[J]. Ocul Immunol Inflamm， 2023∶1-8. DOI： 10.1080/09273948.2023.2173242 .
返回引文位置Google Scholar
百度学术
万方数据
[33]
Singh AD , Lewis H , Schachat AP ,et al. Chapter 62-Lymphoma of the retina and CNS[M]// Singh AD , Damato BE , Pe'er J ,et al. Clinical Ophthalmic Oncology. Philadelphia：Saunders， 2007∶372-3777.
返回引文位置Google Scholar
百度学术
万方数据
[34]
Gu J , Jiang T , Liu S ,et al. Longitudinal analysis of ocular manifestation and interleukin during intravitreal treatment of vitreoretinal lymphoma with methotrexate[J]. Am J Ophthalmol， 2023，251∶189-196. DOI： 10.1016/j.ajo.2023.03.010 .
返回引文位置Google Scholar
百度学术
万方数据
[35]
Zhang Y , Zhang X , Zou D ,et al. Lenalidomide and rituximab regimen combined with intravitreal methotrexate followed by lenalidomide maintenance for primary vitreoretinal lymphoma：a prospective phase Ⅱ study[J/OL]. Front Oncol， 2021，11∶701507[2023-10-12]. http://www.ncbi.nlm.nih.gov/pubmed/34249763. DOI： 10.3389/fonc.2021.701507 .
返回引文位置Google Scholar
百度学术
万方数据
[36]
Zhou X , Zhou X , Shi H ,et al. Reduced frequency of Intravitreal methotrexate injection lowers the risk of Keratopathy in Vitreoretinal lymphoma patients[J/OL]. BMC Ophthalmol， 2020，20(1)∶189[2023-10-12]. http://www.ncbi.nlm.nih.gov/pubmed/32397978. DOI： 10.1186/s12886-020-01464-3 .
返回引文位置Google Scholar
百度学术
万方数据
[37]
Zhao H , Wang X , Mao Y ,et al. Longitudinal observation of OCT imaging is a valuable tool to monitor primary vitreoretinal lymphoma treated with intravitreal injections of methotrexate[J/OL]. BMC Ophthalmol， 2020，20(1)∶10[2023-10-12]. http://www.ncbi.nlm.nih.gov/pubmed/31906917. DOI： 10.1186/s12886-019-1300-1 .
返回引文位置Google Scholar
百度学术
万方数据
[38]
Riemens A , Bromberg J , Touitou V ,et al. Treatment strategies in primary vitreoretinal lymphoma：a 17-center European collaborative study[J]. JAMA Ophthalmol， 2015，133(2)∶191-197. DOI： 10.1001/jamaophthalmol.2014.4755 .
返回引文位置Google Scholar
百度学术
万方数据
[39]
Berenbom A , Davila RM , Lin HS ,et al. Treatment outcomes for primary intraocular lymphoma：implications for external beam radiotherapy[J]. Eye (Lond)， 2007，21(9)∶1198-1201. DOI： 10.1038/sj.eye.6702437 .
返回引文位置Google Scholar
百度学术
万方数据
[40]
Deangelis LM , Hormigo A ．Treatment of primary central nervous system lymphoma[J]. Semin Oncol， 2004，31(5)∶684-692. DOI： 10.1053/j.seminoncol.2004.07.011 .
返回引文位置Google Scholar
百度学术
万方数据
[41]
Morris PG , Correa DD , Yahalom J ,et al. Rituximab，methotrexate，procarbazine，and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma：final results and long-term outcome[J]. J Clin Oncol， 2013，31(31)∶3971-3979. DOI： 10.1200/JCO.2013.50.4910 .
返回引文位置Google Scholar
百度学术
万方数据
[42]
Abrey LE , Batchelor TT , Ferreri AJ ,et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma[J]. J Clin Oncol， 2005，23(22)∶5034-5043. DOI： 10.1200/JCO.2005.13.524 .
返回引文位置Google Scholar
百度学术
万方数据
[43]
Jiang T , Gu J , Liu S ,et al. Retinal changes of primary vitreoretinal lymphoma after intravitreal methotrexate[J/OL]. BMC Ophthalmol， 2022，22(1)∶375[2023-10-16]. http://www.ncbi.nlm.nih.gov/pubmed/36127675. DOI： 10.1186/s12886-022-02604-7 .
返回引文位置Google Scholar
百度学术
万方数据
[44]
Stacey AW , Pulido JS . The Concept of Minimal Residual Disease in the Treatment and Staging of Vitreoretinal Lymphoma[J]. Retina， 2020，40(7)∶1213-1214. DOI： 10.1097/IAE.0000000000002851 .
返回引文位置Google Scholar
百度学术
万方数据
[45]
Cheson BD , Fisher RI , Barrington SF ,et al. Recommendations for initial evaluation，staging，and response assessment of Hodgkin and non-Hodgkin lymphoma：the Lugano classification[J]. J Clin Oncol， 2014，32(27)∶3059-3068. DOI： 10.1200/JCO.2013.54.8800 .
返回引文位置Google Scholar
百度学术
万方数据
[46]
Tilly H , Gomes da Silva M , Vitolo U ,et al. Diffuse large B-cell lymphoma (DLBCL)：ESMO Clinical Practice Guidelines for diagnosis，treatment and follow-up[J]. Ann Oncol， 2015，26Suppl 5∶v116-v125. DOI： 10.1093/annonc/mdv304 .
返回引文位置Google Scholar
百度学术
万方数据
[47]
中国临床肿瘤学会指南工作委员会．中国临床肿瘤学会(CSCO)淋巴瘤诊疗指南2023[M]. 北京：人民卫生出版社， 2023∶15-18.
返回引文位置
备注信息
A
周楠，Email： mocdef.3ab61emit99ohce；
B
魏文斌，Email： mocdef.3ab61rtnibnewiew 　首都医科大学附属北京同仁医院　北京同仁眼科中心　眼内肿瘤诊治研究北京市重点实验室　北京市眼科学与视觉科学重点实验室，北京　100730
C
http：//www.guidelines-registry.cn/，PREPARE-2023CN728
D
http：//www.guidelines-registry.cn/，PREPARE-2023CN728
E
所有作者均声明不存在利益冲突。本文内容与相关产品的生产和销售厂商无经济利益关系
F
本文为专家推荐意见，为临床医疗服务提供指导，不是在各种情况下都必须遵循的医疗标准，也不是为个别特殊个人提供的保健措施。
G
国家自然科学基金 (82220108017、82141128)
首都卫生发展科研专项 (首发2020-1-2052)
北京市科委科技计划项目 (Z201100005520045、Z181100001818003)
评论 （0条）
注册
登录
时间排序
暂无评论，发表第一条评论抢沙发
最新推荐
更多
成人T细胞白血病/淋巴瘤诊断与治疗中国专家共识（2024年版）
中国医师协会血液科医师分会 等
中华内科杂志 2024,63(12)
肺结节诊治中国专家共识（2024年版）
中华医学会呼吸病学分会 等
中华结核和呼吸杂志 2024,47(08)
老年弥漫大B细胞淋巴瘤诊断与治疗中国专家共识（2024年版）
中华医学会血液学分会淋巴细胞疾病学组 等
中华血液学杂志 2024,45(04)
中国心力衰竭诊断和治疗指南2024
中华医学会心血管病学分会 等
中华心血管病杂志 2024,52(03)
MedAI助手（体验版）
文档即答
智问智答
机器翻译
回答内容由人工智能生成，我社无法保证其准确性和完整性，该生成内容不代表我们的态度或观点，仅供参考。
生成快照
文献快照

你好，我可以帮助您更好的了解本文，请向我提问您关注的问题。

0/2000

《中华医学会杂志社用户协议》 | 《隐私政策》

《SparkDesk 用户协议》 | 《SparkDesk 隐私政策》

网信算备340104764864601230055号 | 网信算备340104726288401230013号

技术支持：

历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号
小中大